614 related articles for article (PubMed ID: 26268434)
21. The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview.
Mouhoub E; Domenech P; Ndao M; Reed MB
Front Microbiol; 2021; 12():757858. PubMed ID: 34745066
[TBL] [Abstract][Full Text] [Related]
22. Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice.
Wang LM; Shi CH; Fan XL; Xue Y; Bai YL; Xu ZK
Chin Med J (Engl); 2007 Jul; 120(14):1220-5. PubMed ID: 17697571
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
[TBL] [Abstract][Full Text] [Related]
24. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
25. Recombinant BCG strains expressing chimeric proteins derived from Leptospira protect hamsters against leptospirosis.
Oliveira TL; Rizzi C; da Cunha CEP; Dorneles J; Seixas Neto ACP; Amaral MG; Hartwig DD; Dellagostin OA
Vaccine; 2019 Feb; 37(6):776-782. PubMed ID: 30630695
[TBL] [Abstract][Full Text] [Related]
26. [The application of recombinant Bacillus Calmette-Guérin vaccine and its vector in infectious disease].
Zulpiya T; Ding J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Oct; 30(5):1136-40. PubMed ID: 24459985
[TBL] [Abstract][Full Text] [Related]
27. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
28. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
[TBL] [Abstract][Full Text] [Related]
29. [Strategies for the development of new tuberculosis vaccines].
Fattorini L
Minerva Med; 2007 Apr; 98(2):109-19. PubMed ID: 17519853
[TBL] [Abstract][Full Text] [Related]
30. Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge.
Seixas FK; da Silva EF; Hartwig DD; Cerqueira GM; Amaral M; Fagundes MQ; Dossa RG; Dellagostin OA
Vaccine; 2007 Dec; 26(1):88-95. PubMed ID: 18063449
[TBL] [Abstract][Full Text] [Related]
31. Protective immunity elicited by rBCG vaccines.
Stover CK; Bansal GP; Langerman S; Hanson MS
Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
[TBL] [Abstract][Full Text] [Related]
32. Recent advances with recombinant bacterial vaccine vectors.
Shata MT; Stevceva L; Agwale S; Lewis GK; Hone DM
Mol Med Today; 2000 Feb; 6(2):66-71. PubMed ID: 10652479
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
Deng YH; He HY; Zhang BS
J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells.
Ding GQ; Yu YL; Shen ZJ; Zhou XL; Chen SW; Liao GD; Zhang Y
J Zhejiang Univ Sci B; 2012 May; 13(5):335-41. PubMed ID: 22556170
[TBL] [Abstract][Full Text] [Related]
35. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments.
Dietrich G; Viret JF; Hess J
Vaccine; 2003 Jan; 21(7-8):667-70. PubMed ID: 12531337
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
Alexandroff AB; Nicholson S; Patel PM; Jackson AM
Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008
[TBL] [Abstract][Full Text] [Related]
37. Construction of a recombinant-BCG containing the LMP2A and BZLF1 genes and its significance in the Epstein-Barr virus positive gastric carcinoma.
Xue QJ; Dai J; Li XZ; Zhu W; Si CP; Chen T
J Med Virol; 2014 Oct; 86(10):1780-7. PubMed ID: 24699993
[TBL] [Abstract][Full Text] [Related]
38. Recombinant BCG coexpressing Ag85B, ESAT-6 and Rv3620c elicits specific Th1 immune responses in C57BL/6 mice.
Yang E; Lu Y; Xu Y; Liang Q; Wang C; Wang H; Shen H
Microb Pathog; 2014; 69-70():53-9. PubMed ID: 24726737
[TBL] [Abstract][Full Text] [Related]
39. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
40. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
